Given that retatrutide is not currently licensed in the UK, any access to this compound outside of a clinical trial would be through unlicensed or unregulated channels, carrying both legal implications and significant safety risks
Our healthcare providers work closely with you to minimize any potential side effects and address your unique medical conditions, mental health issues, and lifestyle needs
Tirzepatide is a dual-agonist (GLP-1 + GIP)
In vitro release kinetics of TZP from hydrogel depot In vitro release profiles of TZP and Sema from PNP hydrogels were examined to assess how differences in peptide cargo might influence diffusion and retention
Research is underway for additional neurological disorders, dermatological conditions, respiratory diseases, addictions (food and otherwise), and more
Never discontinue tirzepatide without medical consultation, as abrupt cessation may affect your glycemic control or weight management progress